Clinical Trials Logo

Filter by:
NCT ID: NCT06392789 Not yet recruiting - Insomnia Clinical Trials

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors

Start date: May 15, 2024
Phase: N/A
Study type: Interventional

This clinical trial evaluates the effect of conversational agent, Cecebot, on improving insomnia in stage I-III breast cancer survivors. Sleep disturbance ranks among the top concerns reported by breast cancer survivors and is associated with poor quality of life. Many breast cancer survivors also have decreased physical activity, which may also have a negative impact on sleep and quality of life. Cognitive behavioral therapy for insomnia (CBTi) and physical activity interventions have individually been reported to improve sleep and to have a positive impact on quality of life. Cecebot is a personalized short messaging service (SMS)-based behavioral intervention that combines CBTi and physical activity strategies that may improve sleep for breast cancer survivors.

NCT ID: NCT06392711 Not yet recruiting - Xerostomia Clinical Trials

Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

Start date: May 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells that you produce in your bone marrow called mesenchymal stromal cells (MSCs) into your salivary glands. The main question it aims to answer is whether injection of MSCs into your salivary glands results in any improvement in dry mouth. Participants will: - have bone marrow collected using a needle - undergo a salivary gland ultrasound - complete questionnaires - receive an injection of the bone marrow cells into a salivary gland

NCT ID: NCT06392607 Not yet recruiting - Myopia Clinical Trials

Euclid Phoenix Lens Design Trial 2

Start date: May 2024
Phase: N/A
Study type: Interventional

Lens wettability and subjective comfort of Euclid orthokeratology lenses with and without an enhanced coating will be compared in 50 children. Axial elongation will be monitored in pediatric patients who qualify and consent.

NCT ID: NCT06392542 Not yet recruiting - Depression, Anxiety Clinical Trials

Online Intervention for Transgender/Nonbinary Young Adults' Experiences With Alcohol and Romantic Relationships

Start date: April 2026
Phase: N/A
Study type: Interventional

The objective of this study is to learn more about Whole Selves, an interactive online resource ("intervention") to help transgender and/or nonbinary young adults reflect on their experiences and goals related to both alcohol use and romantic relationships. Existing online interventions focused on alcohol use often aren't a good fit for trans/nonbinary people, and existing relationship education programs don't account for how being trans/nonbinary might influence someone's relationships. For these reasons, the investigator is working with trans/nonbinary young adults and other community stakeholders to create a new intervention specifically for trans/nonbinary young adults. The goals of this clinical trial are to: 1. Find out what transgender/nonbinary young adults think of the Whole Selves intervention in order to improve it 2. See whether the Whole Selves intervention seems to work as expected 3. Help the investigator make plans for a bigger clinical trial of the Whole Selves intervention, which could tell us how well it works In this study, participants will use the Whole Selves intervention; complete online surveys about themselves, their romantic relationship experiences, their mental health, their alcohol use; and provide feedback on the Whole Selves intervention.

NCT ID: NCT06392373 Completed - High Altitude Clinical Trials

High Altitude Muscle Recovery

HAMR
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

To understand alterations in glycogen and molecular regulation of skeletal muscle glucose uptake, glycogen synthesis, and muscle protein recovery when consuming CHO (glucose) or CHO+PRO (glucose + whey) post-exercise during unacclimatized high altitude exposure, randomized crossover double blinded studies will be conducted in the hypobaric/hypoxic chamber at USARIEM Table 1. Briefly, the study consists of a 2 day baseline period at SL followed by two, 3 day trial periods (with the 3rd day being a testing day) at HA. The baseline is separated from trial 1 for a least a day, and trial 1 & 2 separated by at least 4 days. Volunteers will consume CHO (glucose) or CHO+PRO (glucose + whey) drinks post-exercise during unacclimatized high altitude exposure during the two trial periods. The order of the drinks will be randomized (using a random number generator such as randomizer.org) and kept by a study staff not directly involved in data collection to maintain blinding.

NCT ID: NCT06392360 Recruiting - Clinical trials for Metabolic Disturbance

Betaine, Exercise Performance, and Gut Permeability

Start date: May 13, 2024
Phase: N/A
Study type: Interventional

This study will determine if ingestion of 3 g/d betaine versus placebo for two weeks prior to a 60-km cycling time trial will improve performance, moderate exercise-induced gut permeability, and improve metabolic recovery.

NCT ID: NCT06392347 Not yet recruiting - Vasculopathy Clinical Trials

Vessel Wall Imaging

Start date: June 2024
Phase:
Study type: Observational

The purpose of this study is to compare and evaluate a faster MR image that has been optimized to look at your blood vessel walls.

NCT ID: NCT06392295 Not yet recruiting - Prostate Cancer Clinical Trials

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

OCEAN
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.

NCT ID: NCT06392269 Recruiting - Serum Analytes Clinical Trials

A Multi-site Clinical Evaluation of Capillary Blood Samples Collected Using the Tasso+SST Device for Downstream Analyte Testing

Start date: March 18, 2024
Phase:
Study type: Observational

This is a prospective, multi-center study within the U.S. Study participants will take part in two study visits a minimum of 14 days apart. During each visit, participants will self-collect capillary blood samples. Additionally, a healthcare provide will obtain capillary and venous serum samples. All capillary samples will be collected from the upper arm using the Tasso+ device paired with a commercially-available serum separator gel microtainer. The samples will be shipped to a clinical laboratory and tested for various analytes. Expected analyte values for each participant will be based on their venous sample results which will be compared to Tasso sample results

NCT ID: NCT06392126 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Start date: April 16, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10